In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cancer.

Study findings support the recent FDA approval of the immunotherapy agent for patients whose cancers have high number of mutations.

The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.

Breast cancer stem cells from patients with different racial and ethnic backgrounds showed important differences in activation of immune response-related genes in mouse models.

A new study finds that significant symptoms in young and Black patients are more likely to be under-recognized.

A U-M Rogel Cancer Center study provides an updated, more comprehensive look at trends for this rare, aggressive form of breast cancer over the last four decades.